Tesamorelin Research for HIV Lipodystrophy
An evidence-based overview of research examining Tesamorelin in the context of hiv lipodystrophy. This page synthesizes findings from peer-reviewed literature.
Research Summary
The current FDA indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Two pivotal 26-week placebo- controlled trials measured VAT by CT. The FDA label reports between-group VAT differences of -31 and -21 cm2 for the older EGRIFTA formulation; the pooled publication combines the same trials rather than adding 806 independent participants. Continuation maintained VAT reduction to week 52, whereas switching to placebo led to rapid loss of the initial effect. Long-term cardiovascular benefit has not been established.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.